Avatar
Benzinga News source @benzinga.com · Detroit 🇺🇸· Jan 5

#Biotechnology #Epilepsy #ConferenceCall

Link Preview
www.benzinga.com
Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026 - Bright Minds Biosciences (NASDAQ:DRUG)
- Conference Call and Live Webcast at 8AM ET - NEW YORK, Jan.
Avatar
NASDAQ Stock Market News source @nasdaq.com · New York City 🇺🇸· Jan 5

#Biotechnology #AutoimmuneDiseases #ClinicalTrials

Link Preview
www.nasdaq.com
Jade Biosciences To Report Phase I Trial Of JADE101 In 1H2026
(RTTNews) - Jade Biosciences, Inc.
Avatar
Benzinga News source @benzinga.com · Detroit 🇺🇸· Jan 5

#Biotechnology #RNAMedicines #HealthcareInnovation

Link Preview
www.benzinga.com
Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference - WAVE Life Sciences (NASDAQ:WVE)
CAMBRIDGE, Mass.
Avatar
Benzinga News source @benzinga.com · Detroit 🇺🇸· Jan 5

#Biotechnology #Healthcare #InflammatoryDiseases

Link Preview
www.benzinga.com
Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference - Upstream Bio (NASDAQ:UPB)
WALTHAM, Mass.
S
StreetInsider.com News source @streetinsider.com · Jan 5

#Sustainability #SupplyChain #Biotechnology

Link Preview
www.streetinsider.com
WuXi Biologics Achieves ISO 20400 Certification, Setting Benchmark in Sustainable Procurement
WUXI, China, Jan.
F
The Motley Fool News source @fool.com · Jan 3

#Biotechnology #Vaccines #InsiderTrading

Link Preview
www.fool.com
Vaxcyte's Chief Technical Ops Officer Sells Shares | The Motley Fool
Focused on next-generation vaccines for bacterial diseases, this biotech just reported a notable insider sale amid a challenging year.
Avatar
NASDAQ Stock Market News source @nasdaq.com · New York City 🇺🇸· Jan 3

#Vaccines #Biotechnology #InsiderTrading

Link Preview
www.nasdaq.com
Vaxcyte's Chief Technical Ops Officer Sells Shares
Focused on next-generation vaccines for bacterial diseases, this biotech just reported a notable insider sale amid a challenging year.